Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-36294 uniQure N.V. (Exact name of Registrant as specified in its charter) The Netherlands (Stat ...

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~ ~ Today, announced an organizational restructuring intended ...

~ Announced RMAT designation for AMT-130 in Huntington's disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~ ~ Today, announced an organizational restructuring intended ...

LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Lexington, Massachusetts to Genezen, a leading contract development and manufacturing organization specializing in the supply of retroviral vectors, lentiviral vectors, and adeno-associated virus (AAV) technologies. With the transa ...

~ uniQure maintains preferential access to industry-leading manufacturing capabilities to support its pipeline of gene therapy candidates ~ ~ Immediate reduction in cash burn, projected to save $40 million annually ~ LEXINGTON, Mass. and AMSTERDAM, July 23, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of the sale of its global manufacturing facility in Lexington, Mas ...

In this April 6, 2016, photo, Ed Izenstark and his son Chase, 4, pose in St. Charles, Ill. Izenstark ... [+] inherited a genetic predisposition to Huntington's disease from his birth father, but he only learned of his susceptibility to the fatal nerve disorder after requesting information about his adoption from a state agency last December. Illinois state Rep. Sara Feigenholtz, D-Chicago, wants to make adoption records more transparent to help thousands of people across the state access more details about ...

The average comprises 11 short-term price targets ranging from a low of $6 to a high of $32, with a standard deviation of $8.63. While the lowest estimate indicates a decline of 10% from the current price level, the most optimistic estimate points to a 379.8% upside. More than the range, one should note the standard deviation here, as it helps understand the variability of the estimates. The smaller the standard deviation, the greater the agreement among analysts. However, an impressive consensus price targ ...

uniQure N.V. (QURE) surged 76.5% on Jul 9 after it announced updated interim data, including up to 24 months of follow-up data, from 29 treated patients enrolled in the ongoing early to mid-stage studies of AMT130 for Huntington's disease in the United States and EU. Results demonstrated a potential long-term, durable clinical benefit and reduction of a key marker of neurodegeneration upon treatment with the candidate. uniQure is simultaneously conducting two phase I/II studies of AMT-130, with 26 participa ...

This human gene therapy company is expected to post quarterly loss of $1.24 per share in its upcoming report, which represents a year-over-year change of +13.9%. Revenues are expected to be $3.47 million, up 43.2% from the year-ago quarter. Adaptive Biotechnologies' consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.32. Compared to the company's year-ago EPS, this represents a change of +3%. Adaptive Biotechnologies currently boasts a Zacks Rank of #2 (Buy). For ...

~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the composite Unified Huntington's Disease Rating Scale (cUHDRS) at 24 months compared to a propensity score-weighted external control ~ ~ Investor conference call and webcast today at 8:30 a.m. ET ~ "These updated results are exciting and provide compelling evidence of potential therapeutic benefit," stated Victor Sung ...